Señales en vivo de COX.PA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 abr 2023 @ 11:35):

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health...

Stats
Volumen de hoy	246 141
Volumen promedio	196 980
Capitalización de mercado	29.04M
EPS	€0 ( 2024-04-17 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.456
ATR14	€0.0560 (9.49%)

Volumen Correlación

Largo: -0.11 (neutral)

Corto: -0.95 (very strong negative)

Signal:(45.399) Neutral

Nicox SA Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nicox SA Correlación - Moneda/Commodity

-0.85
( strong negative )

-0.53
( weak negative )

0.00
( neutral )

-0.46
( neutral )

0.84
( strong )

Nicox SA Finanzas

Annual	2022
Ingresos:	€5.24M
Beneficio Bruto:	€3.27M (62.40 %)
EPS:	€0

FY	2022
Ingresos:	€5.24M
Beneficio Bruto:	€3.27M (62.40 %)
EPS:	€0

FY	2021
Ingresos:	€8.58M
Beneficio Bruto:	€7.23M (84.27 %)
EPS:	€-1.170

FY	2020
Ingresos:	€14.42M
Beneficio Bruto:	€12.91M (89.49 %)
EPS:	€-0.540

Financial Reports:

No articles found.

Nicox SA

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.